| pubmed-article:14584522 | pubmed:abstractText | The significance of the endothelial cell as a target for antitumor therapy has been recognized for some time, but so far the results of clinical trials exploiting this approach have not been encouraging. The subject is likely to gain new momentum, however, following a number of important recent findings that shed new light on the origins and nature of tumor vasculature. Coupled with rapid developments in the use ofphage-displayed peptide libraries to characterize the human vascular map, as well as highly selective delivery systems, this new understanding of tumor vascular biology should provide many fresh and exciting avenues to explore. | lld:pubmed |
